Replies to post #128498 on Biotech Values

[HattieTheWitch]

I didn’t offer such a number, but it would not be unduly hard to calculate.

I'm sorry - old age, you know. ;-)

Okay, let me put it this way - do you think it is reasonable to expect that MNTA could make a settlement with Amphastar which would would make up for all the shared revenues its going to lose because of the (potential) entry of Amphastar's generic?

IOW, is it likely that MNTA is going to come out of such a settlement worse off (not getting as much money over time) than it would have been in the absence of Amphastar's approval?

Thank you.